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Background: CC-chemokine receptor 7 (CCR7), a known lymph node homing receptor for immune cells, has been
reported as a key molecule in lymph node metastasis. We hypothesized a clinicopathological correlation and
functional causality between CCR7 expression and lymph node metastasis in patients with esophageal squamous
cell carcinoma (ESCC).
Methods: We performed immunohistochemical analysis of 105 consecutive and 61 exclusive pathological T1 ESCC
patients, followed by adhesion assay and in vivo experiment using a newly developed lymph node metastasis
mouse model. The adhesive ability in response to CC-chemokine ligand 21/secondary lymphoid-tissue chemokine
(CCL21/SLC) was assessed in the presence or absence of lymphatic endothelial cells and anti-CCR7 antibody. We
established a heterotopic transplantation mouse model and analyzed lymph node metastasis by quantitative
real-time RT-PCR.
Results: Positive CCR7 expression in immunohistochemistory was detected in 28 (27%) of 105 consecutive patients
and 17 (28%) of 61 T1 patients, which significantly correlated with lymph node metastasis (p = 0.037 and p = 0.040,
respectively) and poor five-year survival (p = 0.013 and p = 0.012, respectively). Adhesion assay revealed an enhanced
adhesive ability of CCR7-expressing cells in response to CCL21/SLC, in particular, in the presence of lymphatic
endothelial cells (p = 0.005). In the mouse model, lymph nodes from mice transplanted with CCR7-expressing
cells showed significantly higher DNA levels at 5 weeks (p = 0.019), indicating a high metastatic potential of
CCR7-expressing cells.
Conclusion: These results demonstrated the significant clinicopathological relationship and functional causality
between CCR7 expression and lymph node metastasis in ESCC patients.
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Esophageal cancer is one of the most malignant solid tu-
mors with a five-year survival rate estimated at <19% [1].
Data reported by the International Union Against Cancer/
American Joint Committee on Cancer (UICC/AJCC)
showed that approximately 44% of initially resected can-
cers of the esophagus and esophagogastric junction had
lymph node metastasis and this high incidence contri-
buted to the causes of poor survival [2]. Nevertheless* Correspondence: htakeuchi@a6.keio.jp
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reproduction in any medium, provided the orsome surgeons, especially those in Japan, have been con-
ducting extended lymphadenectomy to provide better
prognosis, most prospective trials have failed to demon-
strate its survival benefit and its clinical significance is
now considered to be limited [3-6].
One potential approach that might provide a break-
through in this situation is the clarification of the mecha-
nism of lymph node metastasis. A report by Müller et al.
yielded important and noteworthy findings [7]. They
found that the interaction between a chemokine and its
corresponding chemokine receptor had a critical role in
organ-specific cancer metastasis and they suggested thatd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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ligand 21/secondary lymphoid-tissue chemokine (CCL21/
SLC) axis might be responsible for lymph node metastasis.
Chemokine receptor CCR7 was first identified as a gene
receptor of the Epstein–Barr virus (EBV), while CCL21/
SLC and CC-chemokine ligand 19/ EBV-induced mole-
cule ligand chemokine (CCL19/ELC) have since then been
reported to be specific ligands for CCR7 [8]. CCR7 has
been shown to be a homing receptor that controls the
migration of immune cells to secondary lymphoid tissue
organs in response to CCL21/SLC. Müller et al. demon-
strated that this cell homing mechanism applied equally
to CCR7-expressing cancer cells, allowing lymph node
metastasis to be established as a consequence.
Although CCR7 and clinical associations have been
revealed in a large variety of malignant tumors [9], only
a few are currently known for esophageal cancer. In
addition, little is known about the in vitro and in vivo
behavior of CCR7-expressing cells in the sequence of
lymph node metastasis. In this study, we hypothesized
that patients with esophageal squamous cell carcinoma
(ESCC) have a close relationship between CCR7 expres-
sion and lymph node metastasis because a functional
CCR7 on ESCC cells plays a crucial role in lymph node
metastasis in response to CCL21/SLC.Methods
Study patients
We retrospectively surveyed ESCC patients who under-
went radical esophagectomy in Keio University hospital
between 1997 and 2007. Of these patients, we selected
105 consecutive patients from 1997 to 2002 who were
diagnosed with Stage IA-IIIC and 61 patients from 1997
to 2007 who were diagnosed with pathological T1 cancer
(tumor invasion into the lamina propia or submucosa),
according to the UICC staging system (7th edition).Immunohistochemistry
CCR7 expression in tissue samples was assessed by immu-
nohistochemistry (IHC) using the ENVISION+ system
(Dako, Glostrup, Denmark). A rabbit anti-human poly-
clonal IgG CCR7 antibody (1:100; Medical and Biological
Laboratories, Aichi, Japan) was used as a primary anti-
body. Paraffin-embedded human normal spleen and tonsil
tissues were used as positive controls for CCR7. Negative
control sections were treated with a non-immunized
rabbit immunoglobulin fraction (Dako) under equivalent
conditions.
To assess the immunoreactivity, the sections were
scored in terms of their proportion (score 0: −10%, 1;
10%–40%, 2: 40%–70%, 3: >70%) and intensity (score 0:
none, 1: weak, 2: strong) by two investigators (T.I. and
H.T.) who had no knowledge of clinicopathologicalfactors. The total score was calculated by multiplying
the two scores and they were defined as positive at ≥1.
Esophageal cell line
We used 10 established ESCC cell lines from the TE
series (TE-1, 4, 5, 6, 8, 9, 10, 11, 14, and 15) kindly pro-
vided by Dr. Nishihira (Tohoku University, Miyagi,
Japan). Identity of each cell line was confirmed by short
tandem repeat (STR) analysis (data not shown).
RNA extraction and quantitative real-time RT-PCR
Total RNA from each of the 10 TE cell lines was extracted
and analyzed by quantitative real-time RT-PCR using
the 7300 Real Time PCR system (Applied BioSystems,
Carlsbad, CA), TaqMan Gene Expression Master Mix
(Applied BioSystems), and ready-to-use CCR7 primers
(Assay ID: Hs99999080_m1; Applied BioSystems). Glyceral-
dehyde-3-phosphate dehydrogenase (GAPDH) was used as
an internal control. We used human lymphocyte from a
healthy donor as a positive control and distilled water
without the template as a negative control. The relative
quantity of CCR7 mRNA in 10 TE cell lines was calculated
using ΔΔCt method in which TE1 expression level is de-
fined as 1.
Establishment of a stable CCR7-overexpressing cell line
CCR7 mRNA was extracted from TE8 and its full-length
open reading frame (ORF) was amplified and inserted
into the plasmid vector pFLAG-CMV-4 (Sigma Aldrich,
St. Louis, MO). The plasmids were electroporated into
E.coli 5DHα (Takara Bio Inc., Shiga, Japan) and trans-
fected to TE4 cells using Lipofectamine 2000 Reagent
(Invitrogen, Carlsbad, CA). We defined this stable trans-
fectant as TE4CCR7+ in which CCR7 overexpression was
confirmed by western blotting, cell enzyme-linked im-
munosorbent assay (ELISA), and real-time RT-PCR.
Adhesion assay
TE4 and TE4CCR7+ cells were labeled with green 5-
chloromethylfluorescein diacetate (CMFDA; Invitrogen).
To investigate the effect of epithelial cells on cell adhesion,
normal human lung lymphatic microvascular endothelial
cells (HMVEC-LLy; Lonza Walkersville Inc., Walkersville,
MD) were used in this assay, and HMVEC-LLy was
labeled with a red fluorescent dye (CMPTX; Invitrogen).
Chambers were confluent with a monolayer of HMVEC-
LLy. We seeded 5 × 104 cells/well TE4 or TE4CCR7+ and
incubated for 10 min at 37°C with or without human re-
combinant CCL21/SLC (R&D Systems). A blocking assay
was performed using mouse monoclonal anti-CCR7 anti-
body (10 μg/ml; R&D Systems), mouse monoclonal anti-
intercellular adhesion molecule (ICAM)-1 (10 μg/ml;
Abcam, Cambridge, England), or anti-ICAM-2 antibody
(10 μg/ml; Abcam). The number of attached cells in five
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using BIOREVO BZ-9000 microscope (Keyence, Osaka,
Japan). These procedures were repeated at least three
times.
Development of lymph node metastasis model and
quantification of DNA from tumor cells in lymph nodes
Our heterotopic transplantation mouse model of lymph
node metastasis was developed as follows: 1) a subcutane-
ously growing tumor was established by injecting 1 × 107
TE4 or TE4CCR7+ cells into five-week-old nude mice; 2)
after the tumors had developed (4–6 weeks after injec-
tion), they were excised and a small piece (approximately
1 mm3) was transplanted into the right and left elbows of
additional five-week-old nude mice (defined as the TE4
and TE4CCR7+ groups, respectively); 3) the accessory axil-
lary lymph nodes were excised and examined at 3, 4, and
5 weeks after transplantation. Ten lymph nodes from five
nude mice were examined each week, and DNA of each
node was extracted.
We used a human Alu sequence to quantitatively assess
lymph node metastasis. We quantified 90 ng of DNA from
each lymph node using primers for the Alu sequence [10].
The primers were 5’-CGCCTGTAATCCCAGCACTTT-3’
(forward), 3’-CCCAGGCTGGAGTGCAGT-5’ (reverse),
and 5’-FAMCGAGGCGGGCGGATCACCTBHQ1-3’ (Taq-
Man Probe). We used DNA extracted from TE4 cells as a
positive control while that from the lymph nodes of a
non-treated nude mouse was used as a negative control.
The estimated number of cells was calculated based on a
standard curve prepared prior to this experiment (data
not shown, r 2 = 0.998).
Statistical analyses
For statistical analyses, Student’s t-test, Pearson’s χ2 test
or Fisher’s exact probability test was used for assessing
the correlation between CCR7 expression and clinico-
pathological characteristics. The Kaplan–Meier and log-
rank test were used for survival analysis. Student’s t-test
or Welch’s t-test with Bonferroni correction was used
for analysis in adhesion assay. In the mouse model, the
Mann–Whitney U test was used to calculate statistical
significances of the estimated number of cells. All sta-
tistical procedures were performed using IBM SPSS Sta-
tistics (Version 19; IBM, Armonk, NY). A p value of less
than 0.05 was considered statistically significant. This
study was approved by the Institutional Review Board at
Keio University School of Medicine (ref. 20–125).
Results
CCR7 expression and clinicopathological characteristics
We found that 28 of 105 patients (26.7%) were positive
for CCR7 expression (total score >1) and these were re-
ferred to as the CCR7(+) group (n = 28), whereas theremainder were the CCR7(−) group (n = 77) (Table 1).
Representative images of IHC are shown in Figure 1a.
The CCR7(+) patients exhibited a significantly higher
rate of lymph node metastasis (p = 0.037) and a poor
five-year overall survival (OS, 53.2% versus 25.0%,
p = 0.013) (Figure 1b). We then tested whether the cor-
relation was also applicable to early stage ESCC, because
ESCC often leads to early lymph node metastasis when
compared with other solid gastrointestinal cancers. We
assessed 61 patients who were pathologically diagnosed
with T1 cancer, with the result that 17 patients (27.9%)
were classified in the CCR7(+) group (Table 1). The
CCR7(+) group had significant correlations with lymph
node metastasis (p = 0.040) and the histological grade
(p = 0.020) as well as lymphatic and vessel invasions
(p = 0.044 and p = 0.045, respectively). Patients with
positive CCR7 expression also had a poor five-year OS
(81.8% versus 47.1%, p = 0.012) (Figure 1b).
Table 2 indicates the distribution of the total score of
CCR7 expression. The number of patients with lymph
node metastasis did not increase as the score increased.
Thus, no apparent relationship between intensity/pro-
portion of CCR7 expression and lymph node metastasis
was found.
CCR7 mRNA expression in TE cell lines
CCR7 mRNA expression in TE cell lines was assessed by
quantitative real time RT-PCR. (Figure 2a) The CCR7
mRNA expression level was extremely low compared
with human lymphocytes (1.323 × 105), whereas all TE
cell lines expressed CCR7 at different relative copy levels
ranging from 0.215 to 16.8 (median 0.43). This large
difference among the cell lines was also seen in other
studies in which the level of CCR7 expression of another
ESCC cell line or other cancer cell lines was investigated
[7,11,12]. TE4, TE10, TE11, TE14, and TE15 showed the
lowest CCR7 mRNA levels and we selected TE4 for sub-
sequent experiments because TE4 was the only cell line
transplantable to mice among the five cell lines (data not
shown). Then we established 18 TE4CCR7+ cell lines that
overexpressed CCR7 by gene transfer and used one of
the cell lines for further investigation which was trans-
plantable to mice and showed 7.8-fold high CCR7 ex-
pression compared with untreated TE4 (Figure 2b).
Effect of CCL21/SLC on adhesive ability
Figure 3a shows the effect of CCL21/SLC on cell adhe-
sion, while Figure 3b presents a summary of the number
of attached cells. CCL21/SLC significantly increased the
number of attached TE4CCR7+cells, although not with
TE4 cells in the presence of HMVEC-LLy (mean num-
ber ± SD (cells): 119.4 ± 97.6 versus 7.3 ± 5.6, p = 0.005).
TE4CCR7+ cells lost their adhesive abilities when anti-





















Figure 1 Representative immunohistochemistry for CCR7 protein and the five-year overall survival rate in ESCC patients. a. Representative
immunohistochemistry for positive and negative expression of CCR7. b. Five-year overall survival rate in 105 consecutive patients and 61
exclusively T1 ESCC patients.
Table 1 CCR7 expression and clinicopathological characteristics of 105 consecutive patients and exclusively pT1
patients
All patients (n = 105) (%) pT1 patients (n = 61) (%)
CCR7(+) CCR7(−) p CCR7(+) CCR7(−) p
n = 28 (27) n = 77 (73) n = 17 (28) n = 44 (72)










































Present 18 33 7 6
SD: standard deviation.
a: Fisher’s exact probability test, b: Pearson’s χ-square test, c: Student’s t-test.
Irino et al. BMC Cancer 2014, 14:291 Page 4 of 8
http://www.biomedcentral.com/1471-2407/14/291
Table 2 Distribution of immunohistochemical CCR7 score
and lymph node involvement
All patients
CCR7 score 0 1 2 3 4 5 6 Total
No. of patients 77 2 8 1 8 0 9 105
LN (+) 45 2 7 1 5 0 8 68
LN (−) 32 0 1 0 3 0 1 37
pT1 patients
CCR7 score 0 1 2 3 4 5 6 Total
No. of patients 44 1 5 0 9 0 2 61
LN (+) 13 1 3 0 5 0 2 24
LN (−) 31 0 2 0 4 0 0 37
LN: lymph node.
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in the presence of HMVEC-LLy, but only a small dif-
ference was found between the two cell lines in its
absence (10.3 ± 9.7 versus 3.0 ± 2.1, p = 0.012). These re-
sults suggest that CCL21/SCL enhanced the adhesive
ability of CCR7-expressing cells, especially in the pre-
sence of lymphatic endothelial cells. We also investigated
whether ICAM-1 or ICAM-2 was involved in this
adhesion mechanism by adding anti-ICAM-1 and anti-
ICAM-2 antibodies, but we found no significant diffe-
rences before and after the treatment.
Lymph node metastasis in vivo
We established a heterotopic transplantation mouse
















Figure 2 CCR7 mRNA expression in TE cell lines by quantitative real-t
CCR7 mRNA levels were normalized with GAPDH and calculated using the
in TE4 and TE4CCR7+. (*CCR7+ should be written in superscript letter).expressing cells in vivo (Figure 4a). Although the excised
accessory lymph nodes were grossly normal (Figure 4b),
metastatic cells were demonstrated in the lymph nodes
by Hematoxylin and eosin staining (Figure 4c). Figure 4d
shows the estimated number of metastatic cells cal-
culated from the quantitative DNA levels detected in
the excised lymph nodes at 3, 4, and 5 weeks after trans-
plantation. No differences were observed at 3 and
4 weeks after transplantation between the TE4CCR7+ and
TE4 groups, but the TE4CCR7+ group showed signifi-
cantly higher DNA levels at 5 weeks (mean ± SD (esti-
mated number of cells): 15.09 ± 32.93 versus 0.11 ± 0.15,
p = 0.019), indicating the high metastatic potential of
CCR7-expressing cells.
Discussion
Our study had three significant findings about CCR7
and lymph node metastasis in ESCC. First, we demon-
strated that positive CCR7 expression was significantly
correlated with lymph node metastasis and the five-year
survival rate using the largest population of patients with
ESCC. In addition, we also showed that exclusive pT1
patients denoted the same tendency. Second, the adhe-
sive abilities of CCR7-expressing cells were significantly
enhanced in response to CCL21/SLC, which has never
been reported in prior studies. Third, CCR7-expressing
cells had higher metastatic potential in the lymph node
of our heterotopic transplantation mouse model, which
was a newly-developed model in the study of lymph
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Figure 3 Adhesion assay of TE4 and TE4CCR7+ cells. a. Representative adhesion assay for TE4CCR7+ cells with or without CCL21/SLC. TE4CCR7+
cells were dyed using CMFDA (green), while lymphatic endothelial cells (HMVEC-LLy) were dyed using CMPTX (red). b. Number of attached cells
in each experiment.
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between CCR7 and lymph node metastasis in malignant
solid tumors [7,13-15]. However, only three studies have
investigated esophageal cancer [12,16,17]. Our results
confirmed the results obtained in these previous studies,
but with a larger population of patients and we provideda b
c x40 x100
Figure 4 Heterotopic transplantation mouse model for lymph node m
small piece was transplanted into the elbow of another nude mouse. b. Gr
Eosin staining of the excised lymph node (yellow arrow indicates metastati
lymph nodes, as measured by quantitative real-time RT-PCR with the humafurther evidence of the correlation with ESCC. Another
key finding was that patients with pathological T1 ESCC
denoted the same tendency. This fact has rarely been
described because of low incidence of lymph node me-
tastasis in patients at an early stage of other carcinomas,
















etastasis. a. A subcutaneously growing tumor was excised and a
oss appearance of excised accessory lymph nodes. c. Hematoxylin and
c cancer cells). d. Estimated number of cells in the accessory axillary
n Alu sequence.
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sion and frequent lymph node metastasis imply the pos-
sible functional correlation of CCR7 with lymph node
metastasis in ESCC.
Lymphatic invasion seems to have a significant rela-
tionship with positive CCR7 since CCR7 expression sig-
nificantly correlated with lymph node metastasis, but
there was no significant difference in lymphatic invasion
when all patients with ESCC were analyzed. One pos-
sible reason for this is that lymphatic invasion was seen
in most of patients with ESCC (83%), which, if any, re-
quired us more patients to be analyzed to demonstrate a
significant difference. However, patients with both posi-
tive CCR7 and lymphatic invasion accounted for 93% of
all patients with positive CCR7. Moreover, we showed
significant differences in lymphatic and vessel invasion
in pT1 patient population. These facts suggest a poten-
tial relationship between CCR7 expression and lym-
phatic invasion.
The adhesion assay demonstrated an enhanced adhesive
ability of CCR7-expressing cells in response to CCL21/
SLC, especially in the presence of lymphatic endothelial
cells. Yin et al. investigated the functional and genetic im-
portance of heparan sulfate lining on the lymphatic endo-
thelial cells, demonstrating that heparan sulfate plays a
critical role in mediating chemokine-dependent tumor cell
trafficking in the lymphatic microenvironment [19]. An-
other study by Peramo et al. showed that heparan sulfate
is a preferred substrate for adhesion while it is attenuated
by heparin use [20]. Taken together, CCR7-mediated cell
adhesion may be facilitated in the presence of lymphatic
endothelial cells, presumably through heparan sulfate
glycosaminoglycans. For naïve T cells, subsequent firm
binding was established by ICAM-1 and ICAM-2; how-
ever, for cancer cells, this binding could not be blocked by
anti-ICAM-1 and ICAM-2 antibodies. Further study will
be required to clarify which molecule is involved in this
firm binding to lymphatic cells since it can be a potential
target for preventing cancer cell adhesion as well.
Transferring these findings to clinical practice de-
mands a clinically accurate and reliable animal model.
We demonstrated the high metastatic potential of
CCR7-expressing cells using a heterotopic transplan-
tation mouse model. With regard to animal models,
Cunningham et al. and Wiley et al. have also reported
the high metastatic potential of CCR7-expressing cells
for breast cancer and malignant melanoma metastasis,
respectively [21,22]. Our results objectively demon-
strated not only the high metastatic potential of CCR7-
expressing cells but also an earlier metastasis compared
with wild-type cells. This result was comparable with
that of our clinical study of T1 ESCC. Therefore, this
may provide a molecular explanation for early lymph
node metastasis in ESCC patients.Our findings suggest potential therapeutic strategies for
lymph node metastasis, i.e., CCR7 may be a promising
biomarker and molecular target for lymph node metasta-
sis. First, CCR7 could be a candidate that can predict
lymph node metastasis. T1 patients with CCR7-negative
ESCC may be at a low risk of lymph node metastasis;
therefore, they could receive less invasive therapy, thereby
avoiding radical esophagectomy. Second, in terms of mo-
lecular therapy, Lanati et al. showed Chemotrap-1, an
engineered CCL21-soluble inhibitor that could block the
chemokine-induced migration of cancer cells, reduced
lymphatic invasion, tracking, and metastasis in vivo [23].
Taken together, our results and this evidence of an inhibi-
tory molecule could bring CCR7-targeted therapy closer
to clinical reality. Our findings provide further evidence
for the mechanism of CCR7-mediated lymph node metas-
tasis, leading to novel therapeutic strategies for regulating
lymph node metastasis.
Conclusions
In this study, we demonstrated the significant clinicopath-
ological relationship and functional causality between
CCR7 expression and lymph node metastasis in ESCC pa-
tients. CCR7 expression significantly correlated with poor
outcomes in ESCC patients.
The adhesive abilities of CCR7-expressing cells were sig-
nificantly enhanced in response to CCL21/SLC. CCR7-
expressing cells had higher metastatic potential in the
lymph node of our heterotopic transplantation mouse
model, which was a newly-developed model in the study
of lymph node metastasis.
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